![PDF) First User Experiences With a Novel Touchscreen-Based Insulin Pump System in Daily Life of Patients With Type 1 Diabetes Experienced in Insulin Pump Therapy PDF) First User Experiences With a Novel Touchscreen-Based Insulin Pump System in Daily Life of Patients With Type 1 Diabetes Experienced in Insulin Pump Therapy](https://i1.rgstatic.net/publication/326364476_First_User_Experiences_With_a_Novel_Touchscreen-Based_Insulin_Pump_System_in_Daily_Life_of_Patients_With_Type_1_Diabetes_Experienced_in_Insulin_Pump_Therapy/links/5b4eeb06a6fdcc8dae2810b9/largepreview.png)
PDF) First User Experiences With a Novel Touchscreen-Based Insulin Pump System in Daily Life of Patients With Type 1 Diabetes Experienced in Insulin Pump Therapy
![Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis - Kidney International Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis - Kidney International](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/dd256a13-fadf-4c0c-af23-1000c700700e/fx1_lrg.jpg)
Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis - Kidney International
![Novo Nordisk's Fiasp (insulin aspart injection) Receives the FDA's Approval for use in Insulin Infusion Pumps to Treat Type 1 or Type 2 Diabetes | PharmaShots Novo Nordisk's Fiasp (insulin aspart injection) Receives the FDA's Approval for use in Insulin Infusion Pumps to Treat Type 1 or Type 2 Diabetes | PharmaShots](https://pharmashots.com/wp-content/uploads/2019/10/Fiasp-850x560.jpg)